Which biological therapy is commonly used in severe asthma treatment?

Omalizumab is a monoclonal antibody designed specifically for the treatment of severe asthma that is allergic in nature. It works by binding to immunoglobulin E (IgE) antibodies, which play a key role in the allergic response and contribute to asthma symptoms. By inhibiting the action of IgE, omalizumab reduces the frequency of asthma exacerbations and helps improve overall asthma control in patients with a history of allergic asthma.

This therapy is particularly beneficial for individuals who have not responded adequately to standard asthma medications or those with high eosinophil counts and significant allergic triggers. It is administered via subcutaneous injection and is often used in conjunction with other asthma treatments for better management.

Other options, while relevant to overall asthma treatment, are not categorized as biological therapies for severe asthma. Escitalopram is an antidepressant and is not used in the treatment of asthma. Prednisone is a steroid that may be used during exacerbations but isn’t considered a long-term biological therapy. Montelukast is a leukotriene receptor antagonist that can be helpful but does not fall under the category of biological therapies specifically targeting severe asthma.